Patent · US Active

O-glycan sialylated recombinant glycoproteins

US10793839B2 · kind B2 · utility

0Cited by

1References

4Claims

0Family size

Assignee

CEVEC Pharmaceuticals GmbH · DE

Inventors

Silke Wissing · Cologne, DE
Jens Wölfel · Langenfeld, DE
Nicole Faust · Cologne, DE

Key dates

Filing date	Aug 21, 2018
Grant date	Oct 6, 2020
Priority date	—
Expiry date	Aug 21, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y204/99004
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention relates to cell lines that are genetically modified to overexpress a β-galactoside α-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as to respective recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.